Xcell Biosciences Announces Collaboration with ElevateBio
ElevateBio to Highlight Growth of Business Driven By Gene Editing Partnerships
Even with $401 million in the bank—thanks to one of the year’s largest biotech fundraisings—ElevateBio is still shaving off some preclinical work resulting in layoffs that will affect 13% of the workforce.
WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming cell and gene therapies, today announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors. ElevateBio’s syndicate now includes new investors Woodline, Lee Family Office (Asia), and R&D partner Novo Nordisk, as well as existing investors: Matrix Capital Management, The Invus Group, Emerson Collective, SoftBank Vision Fund 2, Fidelity Management & Research Company, MPM Capital, F2 Ventures, Redmile Group, EcoR1 Capital, Samsara BioCapital, Surveyor Capital (a Citadel company), EDBI, Vertex Ventures, iTochu, and a large institutional investor. In connection with the financing, Khalil Barrage, Managing Director of The Invus Group, was appointed to ElevateBio’s Board of Directors.
WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023, in Los Angeles, CA. The poster presentations will detail ElevateBio’s research and process development across its lentiviral vector (LVV) and adeno-associated virus (AAV) platforms, optimized to further increase yields and product quality for ease of transition when scaling from research to clinical manufacturing and streamlining product development.
Affini-T is the latest to sign on with ElevateBio, former Alexion head David Hallal’s one-stop-shop for cell and gene therapy manufacturing. Affini-T will use ElevateBio’s lentiviral vector system to engineer cell therapies targeted at KRAS.
ElevateBio, a privately held biotechnology company that’s raised hundreds of millions of dollars from private investors, signed a 30-year partnership with the University of Pittsburgh to speed development of “highly innovative” cell and gene therapies.
WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has partnered with the California Institute for Regenerative Medicine (CIRM) to advance the discovery and development of regenerative medicine as part of CIRM’s Industry Alliance Program. Through the partnership, ElevateBio will provide access to high quality, well-characterized iPSC lines to academic institutions and biopharmaceutical companies that are awarded CIRM Discovery and Translational Grants. ElevateBio will also offer access to its viral vector technology, process development, analytical development, and Good Manufacturing Practice (GMP) manufacturing capabilities that are part of its integrated ecosystem built to power the cell and gene therapy industry.
WALTHAM, Mass.--(BUSINESS WIRE)--ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has formed a new company co-founded by George Daley, M.D, Ph.D., and Boston Children’s Hospital to develop allogeneic immune cell therapies based on a novel platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs). This proprietary differentiation process overcomes the tendency of iPSCs to generate immature, embryonic blood cell types, and enables the generation of multiple subtypes of immune cells that display mature molecular signatures similar to T cells from adult blood. The peer-reviewed publication in the journal Cell Stem Cell showed that iPSC-derived mature ?? T cells exhibited antitumor activity and cytokine secretion and could serve as an ideal source for the development of allogeneic “off-the-shelf” therapies.
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ElevateBio LLC (ElevateBio), a cell and gene therapy technology company focused on powering transformative cell and gene therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment (PTA). This patent, issued to LifeEDIT Therapeutics, Inc. (Life Edit), is the first to provide composition and methods of use protection for various RNA-guided nucleases (RGNs) in Life Edit’s gene editing platform. Life Edit is an ElevateBio company and holds an array of novel RGNs and base editors.